| Prev Close | 94.32 |
| Open | 94.38 |
| Day Low/High | 91.40 / 94.53 |
| 52 Wk Low/High | 63.29 / 125.86 |
| Volume | 4.96M |
| Avg Volume | 7.52M |
| Exchange | NYSE |
| Shares Outstanding | 1.59B |
| Market Cap | 146.93B |
| EPS | 3.30 |
| P/E Ratio | 28.36 |
| Div & Yield | 3.84 (2.84%) |
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
The drug company generates about 60% of revenue outside the U.S.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates
These names are displaying signs of either bullish or bearish reversal patterns over the past week.
The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?
Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.
Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.
Here's what you need to know now for Thursday, March 22.
No sector offered respite from Thursday's tariff-inspired selloff.
The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.
Just not a great day.
- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally
- Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
- Endometriosis affects an estimated one in 10 women of reproductive age, but diagnosis can take up to six to 10 years(1,2)
Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau
Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.
There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.
Traders should still be long and looking for higher highs. Let's check the charts and indicators again.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.
A roundup of biotech names with actions pending at the FDA in coming weeks.
